Beckman Coulter Diagnostics, a clinical diagnostics leader, has received US Food and Drug Administration (FDA) clearance for its new DxC 500 AU Chemistry Analyser, an automated chemistry analyser, expanding the company's clinical chemistry offering and demonstrating ongoing commitment to product innovation in the in vitro diagnostic industry.

Designed for small-to-medium-sized laboratories, the DxC 500 AU Chemistry Analyser is one of several recent Beckman Coulter solutions designed to optimise laboratory workflows and support critical clinical decisions.

The DxC 500 AU Chemistry Analyser uses standardised assays and reagents found across Beckman Coulter's portfolio of AU clinical chemistry analysers. Using standardised assays and reagents facilitates timely and accurate patient results for both independent laboratories and those part of integrated networks, delivering consistent, harmonized results across AU platforms for clinical decision-making and patient outcomes.

Beckman Coulter is part of the Danaher Corporation family of global science and technology companies. Headquartered in California, US, it has more than 11,000 global team members.